Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
hiv infections - drug therapy (21) 21
index medicus (16) 16
ccr5 receptor antagonists (13) 13
female (13) 13
infectious diseases (13) 13
male (13) 13
cyclohexanes - therapeutic use (12) 12
maraviroc (12) 12
triazoles - therapeutic use (12) 12
viral load (12) 12
virology (12) 12
adult (11) 11
hiv (11) 11
hiv infections - virology (11) 11
anti-hiv agents - therapeutic use (10) 10
hiv-1 - drug effects (10) 10
immunology (10) 10
middle aged (10) 10
hiv infection (9) 9
cd4 lymphocyte count (8) 8
hiv-1 - genetics (8) 8
infection (8) 8
adolescent (7) 7
aged (7) 7
animals (7) 7
efficacy (7) 7
health aspects (7) 7
hiv infections - immunology (7) 7
hiv-1 (7) 7
human immunodeficiency virus--hiv (7) 7
pharmacology & pharmacy (7) 7
treatment outcome (7) 7
anti-hiv agents - pharmacology (6) 6
ccr5 antagonist (6) 6
cyclohexanes - adverse effects (6) 6
cyclohexanes - pharmacology (6) 6
drug therapy (6) 6
drug therapy, combination (6) 6
hiv fusion inhibitors - therapeutic use (6) 6
rna, viral - blood (6) 6
triazoles - adverse effects (6) 6
triazoles - pharmacology (6) 6
viruses (6) 6
aids (5) 5
double-blind method (5) 5
hiv-1 - isolation & purification (5) 5
inhibitor (5) 5
south africa (5) 5
treatment-experienced patients (5) 5
tropism (5) 5
young adult (5) 5
abridged index medicus (4) 4
amino acid sequence (4) 4
anti-hiv agents - adverse effects (4) 4
anti-hiv agents - pharmacokinetics (4) 4
antiretroviral therapy (4) 4
antiviral agents (4) 4
care and treatment (4) 4
clinical-trials (4) 4
coreceptor usage (4) 4
cyclohexanes - pharmacokinetics (4) 4
genotype (4) 4
hiv fusion inhibitors - adverse effects (4) 4
hiv patients (4) 4
pan troglodytes (4) 4
randomized controlled trials as topic (4) 4
risk (4) 4
therapy (4) 4
triazoles - pharmacokinetics (4) 4
virus diseases (4) 4
aids vaccines - immunology (3) 3
analysis (3) 3
ccr5 (3) 3
clinical trials as topic (3) 3
computer simulation (3) 3
dose-response relationship, drug (3) 3
drug resistance (3) 3
drug resistance, viral (3) 3
entry (3) 3
glycoprotein (3) 3
gp120 (3) 3
hiv-1 - physiology (3) 3
hiv/aids (3) 3
k ze virology (3) 3
molecular sequence data (3) 3
phenotype (3) 3
phylogeny (3) 3
prognostic value (3) 3
receptors, ccr5 - genetics (3) 3
receptors, ccr5 - metabolism (3) 3
research article (3) 3
ritonavir (3) 3
safety (3) 3
subgroup (3) 3
usage (3) 3
virus (3) 3
acquired immune deficiency syndrome--aids (2) 2
aids/hiv (2) 2
anti-hiv agents - administration & dosage (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
: Development of maraviroc and an HIV tropism assay
by van der Ryst, Elna and Heera, Jayvant and Demarest, James and Knirsch, Charles
Annals of the New York Academy of Sciences, ISSN 0077-8923, 06/2015, Volume 1346, Issue 1, pp. 7 - 17
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
by Van Der Ryst, Elna
Frontiers in Immunology, ISSN 1664-3224, 2015, Volume 6, p. 277
Tropism | CCR5 antagonist | HIV | Antiretroviral drug | HIV-1 RNA | antiretroviral drug | VIRUS | ENTRY | CLINICAL-TRIALS | tropism | RESISTANCE | RECEPTOR | IMMUNOLOGY | Hiv-1 rna
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
by Gulick, Roy M and Lalezari, Jacob and Goodrich, James and Clumeck, Nathan and DeJesus, Edwin and Horban, Andrzej and Nadler, Jeffrey and Clotet, Bonaventura and Karlsson, Anders and Wohlfeiler, Michael and Montana, John B and McHale, Mary and Sullivan, John and Ridgway, Caroline and Felstead, Steve and Dunne, Michael W and van der Ryst, Elna and Mayer, Howard and MOTIVATE Study Teams
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
The CCR5 coreceptor may be a therapeutic target to block HIV infection. HIV-1–infected patients who had received previous antiretroviral treatment were... 
MEDICINE, GENERAL & INTERNAL | CORECEPTOR USE | CYP3A4 INHIBITORS | EFFICACY | TREATMENT-EXPERIENCED PATIENTS | CLINICAL-TRIALS | CCR5 INHIBITOR | ANTIRETROVIRAL THERAPY | RESISTANT HIV-1 | HEALTHY-VOLUNTEERS | DISEASE PROGRESSION | Triazoles - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Male | RNA, Viral - blood | Viral Load | Cyclohexanes - therapeutic use | HIV-1 - chemistry | Treatment Failure | Adult | Female | Cyclohexanes - adverse effects | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | HIV patients | Care and treatment | Usage | Maraviroc | HIV infection | Health aspects | Antiretroviral drugs | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
by David A. Cooper and Jayvant Heera and James Goodrich and Margaret Tawadrous and Michael Saag and Edwin DeJesus and Nathan Clumeck and Sharon Walmsley and Naitee Ting and Eoin Coakley and Jacqueline D. Reeves and Gustavo Reyes-Teran and Mike Westby and Elna Van Der Ryst and Prudence Ive and Lerato Mohapi and Horacio Mingrone and Andrzej Horban and Frances Hackman and John Sullivan and Howard Mayer and MERIT Study Team
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir
by Mike Westby and Marilyn Lewis and Jeannette Whitcomb and Mike Youle and Anton L. Pozniak and Ian T. James and Tim M. Jenkins and Manos Perros and Elna van der Ryst
Journal of Virology, ISSN 0022-538X, 05/2006, Volume 80, Issue 10, pp. 4909 - 4920
Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
V3 LOOP | CELLULAR TROPISM | VIROLOGY | CHEMOKINE RECEPTOR | SYNCYTIUM-INDUCING PHENOTYPE | AIDS | CORECEPTOR USAGE | INFECTION | INHIBITOR | PROGNOSTIC VALUE | DISEASE PROGRESSION | Anti-HIV Agents - pharmacology | HIV Infections - blood | Cell Line | HIV-1 - drug effects | Cyclohexanes - pharmacology | HIV Infections - virology | Humans | Receptors, CCR5 - blood | Phylogeny | HIV-1 - genetics | Genetic Variation | Triazoles - pharmacology | Cyclohexanes - therapeutic use | HIV-1 - physiology | Genes, env | Recombination, Genetic | HIV Envelope Protein gp160 - genetics | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Clone Cells | CCR5 Receptor Antagonists | Evolution, Molecular | Receptors, CXCR4 - blood | Triazoles - therapeutic use | Vaccines and Antiviral Agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
by Ryst, Elna and Heera, Jayvant and Demarest, James and Knirsch, Charles
Annals of the New York Academy of Sciences, ISSN 0077-8923, 06/2015, Volume 1346, Issue 1, pp. 7 - 17
Assays to identify infectious organisms are critical for diagnosis and enabling the development of therapeutic agents. The demonstration that individuals with... 
tropism | antiretroviral | diagnostic | HIV | assay | Assay | Tropism | Antiretroviral | Diagnostic | MEDICINE, RESEARCH & EXPERIMENTAL | PHENOTYPIC ASSAY | ENHANCED SENSITIVITY | VIROLOGICAL RESPONSE | INDIVIDUALS | TREATMENT-EXPERIENCED PATIENTS | IMMUNODEFICIENCY-VIRUS TYPE-1 | ANTIRETROVIRAL DRUG-RESISTANCE | PHARMACOLOGY & PHARMACY | CORECEPTOR USAGE | INFECTION | TREATMENT-NAIVE PATIENTS | Drug Evaluation, Preclinical - methods | HIV-1 - drug effects | Triazoles - chemistry | Cyclohexanes - pharmacology | Humans | Receptors, CCR5 - drug effects | Biological Assay - methods | Clinical Trials as Topic | Anti-HIV Agents - chemical synthesis | Cyclohexanes - chemical synthesis | Triazoles - pharmacology | Anti-HIV Agents - chemistry | Receptors, CCR5 - metabolism | HIV-1 - physiology | Viral Tropism - drug effects | Drug Design | Anti-HIV Agents - therapeutic use | Cyclohexanes - chemistry | HIV Infections - drug therapy | Triazoles - chemical synthesis | HIV testing | Antiviral agents | HIV (Viruses) | Drug therapy | HIV infection | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: The People Living with HIV Stigma Index
by Dos Santos, Monika M.L and Kruger, Pieter and Mellors, Shaun E and Wolvaardt, Gustaaf and Van Der Ryst, Elna
BMC Public Health, ISSN 1471-2458, 01/2014, Volume 14, Issue 1, pp. 80 - 80
Background: The continued presence of stigma and its persistence even in areas where HIV prevalence is high makes it an extraordinarily important, yet... 
HIV/AIDS | Discrimination | Stigma | South African context | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | AIDS-RELATED STIGMA | MEN | SEX | RISK | HEALTH | Employment - statistics & numerical data | Health Services Accessibility - statistics & numerical data | Cross-Sectional Studies | Prejudice - statistics & numerical data | Humans | Middle Aged | South Africa - epidemiology | HIV Infections - psychology | Male | Stereotyping | Self Disclosure | Young Adult | Adolescent | Adult | Female | Interviews as Topic | Surveys and Questionnaires | Measurement | Surveys | Substance abuse treatment | Statistical analysis | Disease | Prejudice | Alliances | Acquired immune deficiency syndrome--AIDS | Womens health | Human immunodeficiency virus--HIV | Addictive behaviors | Behavior | Public health | Field study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1
by Michael Saag and James Goodrich and Gerd Fätkenheuer and Bonaventura Clotet and Nathan Clumeck and John Sullivan and Mike Westby and Elna van der Ryst and Howard Mayer and A4001029 Study Grp and A4001029 Study Group
The Journal of Infectious Diseases, ISSN 0022-1899, 6/2009, Volume 199, Issue 11, pp. 1638 - 1647
Background. Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual- or mixed-tropic strains of human immunodeficiency virus type 1 (HIV-1). A... 
HIV/AIDS | Tropisms | Medical treatment failures | RNA | Antivirals | Placebos | Viruses | Medications | Dosage | Fees | HIV 1 | CCR5 ANTAGONIST | INFECTIOUS DISEASES | EFFICACY | INHIBITOR | Triazoles - adverse effects | Double-Blind Method | Humans | Middle Aged | Genotype | Male | HIV Fusion Inhibitors - adverse effects | Viral Load | HIV Fusion Inhibitors - therapeutic use | Patient Selection | Young Adult | Cyclohexanes - therapeutic use | Phenotype | Least-Squares Analysis | Adult | Female | HIV - genetics | HIV Infections - drug therapy | Aged | Cyclohexanes - adverse effects | Triazoles - therapeutic use | Usage | Drug therapy, Combination | Maraviroc | Drug therapy | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
by Fätkenheuer, Gerd and Nelson, Mark and Lazzarin, Adriano and Konourina, Irina and Hoepelman, Andy I.M and Lampiris, Harry and Hirschel, Bernard and Tebas, Pablo and Raffi, François and Trottier, Benoit and Bellos, Nicholaos and Saag, Michael and Cooper, David A and Westby, Mike and Tawadrous, Margaret and Sullivan, John F and Ridgway, Caroline and Dunne, Michael W and Felstead, Steve and Mayer, Howard and van der Ryst, Elna and MOTIVATE 2 Study Team and MOTIVATE 1 Study Team and MOTIVATE 1 and MOTIVATE 2 Study Teams
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1442 - 1455
In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48... 
CCR5 ANTAGONIST | MEDICINE, GENERAL & INTERNAL | EFFICACY | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | ACTIVE ANTIRETROVIRAL THERAPY | DRUG-RESISTANT HIV-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | HEPATITIS-C | PROGNOSTIC VALUE | Triazoles - adverse effects | Humans | Middle Aged | Receptors, CCR5 - genetics | Male | RNA, Viral - blood | Hepatitis B - blood | Viral Load | Hepatitis B - complications | Cyclohexanes - therapeutic use | HIV Infections - immunology | Ethnic Groups | HIV Envelope Protein gp41 - therapeutic use | HIV-1 - chemistry | Hepatitis C - blood | Adult | Female | Hepatitis C - complications | Cyclohexanes - adverse effects | Drug Therapy, Combination | Odds Ratio | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Genotype | Treatment Outcome | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Transaminases - blood | Aged | Peptide Fragments - therapeutic use | Antiviral agents | Care and treatment | Maraviroc | Comparative analysis | Health aspects | HIV infection | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
by Giaquinto, Carlo and Mawela, Muthuhadini Patience and Chokephaibulkit, Kulkanya and Negra, Marinella Della and Mitha, Ismail Haroon and Fourie, Jan and Fang, Annie and van der Ryst, Elna and Valluri, Srinivas Rao and Vourvahis, Manoli and Zhang-Roper, Rebecca Yanhui and Craig, Charles and McFadyen, Lynn and Clark, Andrew and Heera, Jayvant
The Pediatric Infectious Disease Journal, ISSN 0891-3668, 05/2018, Volume 37, Issue 5, pp. 459 - 465
BACKGROUND:Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031... 
HIV-1 - drug effects | CCR5 Receptor Antagonists - therapeutic use | Humans | Maraviroc - adverse effects | Maraviroc - therapeutic use | Child, Preschool | Male | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | CCR5 Receptor Antagonists - pharmacokinetics | HIV Fusion Inhibitors - therapeutic use | Maraviroc - pharmacokinetics | CCR5 Receptor Antagonists - adverse effects | HIV Fusion Inhibitors - pharmacokinetics | Adolescent | Receptors, CCR5 | Female | HIV Infections - drug therapy | Viral Tropism | Viral Load - drug effects | Child | HIV infection in children | Models | Maraviroc | Drug therapy | Pharmacokinetics | Patient outcomes | pharmacokinetics | HIV Reports | maraviroc | HIV | CCR5 | pediatric
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings
by Cooper, David A and Heera, Jayvant and Ive, Prudence and Botes, Mariette and Dejesus, Edwin and Burnside, Robert and Clumeck, Nathan and Walmsley, Sharon and Lazzarin, Adriano and Mukwaya, Geoffrey and Saag, Michael and Van Der Ryst, Elna
AIDS, ISSN 0269-9370, 03/2014, Volume 28, Issue 5, pp. 717 - 725
Objective: Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with... 
HIV-1 | Treatment-naive | Maraviroc | Efavirenz | Long term | Randomized controlled trial | Antiretroviral therapy | treatment-naive | INFECTIOUS DISEASES | maraviroc | REDUCED RISK | antiretroviral therapy | IMMUNOLOGY | CHEMOKINE RECEPTOR CCR5 | DEFICIENCY | randomized controlled trial | INDIVIDUALS | VIROLOGY | TREATMENT-EXPERIENCED PATIENTS | CLINICAL-TRIALS | IMMUNODEFICIENCY-VIRUS TYPE-1 | INFECTION | long term | HEPATOTOXICITY | ASSOCIATION | efavirenz | Triazoles - adverse effects | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | Viral Load | Young Adult | Cyclohexanes - therapeutic use | HIV-1 - isolation & purification | Adult | Anti-HIV Agents - therapeutic use | Female | Cyclohexanes - adverse effects | Antiretroviral Therapy, Highly Active - methods | Triazoles - therapeutic use | Double-Blind Method | Anti-HIV Agents - adverse effects | HIV Infections - virology | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Benzoxazines - therapeutic use | Drug-Related Side Effects and Adverse Reactions - epidemiology | Adolescent | HIV Infections - drug therapy | Aged | Clinical Science
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials
by Lewis, Marilyn and Mori, Julie and Toma, Jonathan and Mosley, Mike and Huang, Wei and Simpson, Paul and Mansfield, Roy and Craig, Charles and van der Ryst, Elna and Robertson, David L and Whitcomb, Jeannette M and Westby, Mike
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, pp. e0204099 - e0204099
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from... 
SI PHENOTYPE | VIRUS | ENTRY | MULTIDISCIPLINARY SCIENCES | CROSS-RESISTANCE | CORECEPTOR USAGE | CCR5 | PROGNOSTIC VALUE | BINDING | TREATMENT-NAIVE PATIENTS | SMALL-MOLECULE INHIBITOR | Care and treatment | Gene mutations | Genotype | Development and progression | Genetic aspects | Health aspects | HIV infection | Tropism | CCR5 protein | Divergence | Sensitivity analysis | Amino acid sequence | Viruses | Phylogeny | CXCR4 protein | Natural selection | Disease resistance | Reversion | Mutagenesis | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Site-directed mutagenesis | Failure analysis | Sensitivity enhancement | Mutation | Inhibition | Pretreatment | Genotypes | Index Medicus | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
by Plettenberg, Andreas and Staszewski, Schlomo and Sullivan, John F and van der Ryst, Elna and Youle, Mike and Johnson, Margaret A and Saag, Michael S and Dezube, Bruce J and Jenkins, Tim M and Ridgway, Caroline and Goebel, Frank D and Abel, Samantha and Fätkenheuer, Gerd and Pozniak, Anton L and James, Ian T and Rockstroh, Jürgen K and Medhurst, Christine and Hoepelman, Andy I M
Nature Medicine, ISSN 1078-8956, 11/2005, Volume 11, Issue 11, pp. 1170 - 1172
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for... 
MEDICINE, RESEARCH & EXPERIMENTAL | IN-VITRO | GENE | SAFETY | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADULTS | AIDS | INHIBITOR | DELETION | CELL BIOLOGY | HIV Infections - blood | Area Under Curve | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Triazoles - antagonists & inhibitors | RNA, Viral - blood | Treatment Outcome | Randomized Controlled Trials as Topic | Anti-HIV Agents - administration & dosage | Dose-Response Relationship, Drug | Cyclohexanes - therapeutic use | Time Factors | Viral Load - statistics & numerical data | Cyclohexanes - antagonists & inhibitors | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | CCR5 Receptor Antagonists | Clinical Trials, Phase II as Topic | Triazoles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights